Glycemic control and cardiovascular mortality

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 18, Issue 2, 2011, Pages 104-109

  Riddle, Matthew C ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

cardiovascular risk; hyperglycemia; intensive glycemic treatment; type 2 diabetes

Indexed keywords

INSULIN; METFORMIN; SULFONYLUREA;

ARTICLE; CARDIOVASCULAR RISK; DIABETES CONTROL; FOLLOW UP; GLYCEMIC CONTROL; HYPERGLYCEMIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIC AGENTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952408212     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283446b7e     Document Type: Article

References (16)

1. Sung J, Song Y-M, Ebrahim S, Lawlor DA. Fasting blood glucose and the risk of stroke and myocardial infarction. Circulation 2009; 119:812-819.
2. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375:2215-2222.
3. Saydah S, Tao M, Imperatore G, Gregg E. GHb level and subsequent mortality among adults in the U.S. Diabetes Care 2009; 32:1440-1446.
4. Magliano DJ, Soderberg S, Zimmet PZ, et al. Mortality, all cause and cardio-vascular disease, over 15 years in multiethnic Mauritius. Impact of diabetes and intermediate forms of glucose tolerance. Diabetes Care 2010; 33:1983-1989.
5. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643-2653.
6. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577-1589.
7. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572.
8. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular com-plicationsin veteranswith type 2diabetes. N Engl J Med 2009;360:129-139.
9. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559.
10. Turnbull FM,Abraira C, Anderson RJ,et al.Intensiveglucosecontroland macro-vascular outcomes in type 2 diabetes. Diabetologia 2009; 52:2288-2298.
11. Kelly TN, Bazzano LA, Fonseca VA, et al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 151:394-403.
12. Calles-Escandon J, Lovato LC, Simons-Morton DG, et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by base-line subgroup characteristics. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; 33:721-727.
13. Riddle MC, Ambrosius ST, Brillon DJ, et al. Epidemiologic relationships between A1c and all-cause mortality during a median 3.4-year follow-up of glycemictreatment in the ACCORDtrial. Diabetes Care 2010; 33:983-990.
14. Bonds DE, Miller ME, Bergenstal RM, et al. The association between sympto-matic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiologic analysis of the ACCORD study. BMJ 2010; 340:b4909.
15. Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline character-istics, glycaemictreatmentapproach,and glycated hemoglobin concentration on the risk of severe hypglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010; 340:b5444.
16. The ORIGIN Trial Investigators. Rationale, design, and baseline character-istics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008; 155:26-32.